Press Enter to search · ESC to close

AI × Crypto

AriBio’s AR1001 Slows Alzheimer’s Progression by 31% in Phase III Trial

AriBio presented results from its global Phase III POLARIS-AD trial of oral drug candidate AR1001 at the CTAD conference, showing a 31% reduction in disease progression in the monotherapy population. The study enrolled 1,535 participants with early Alzheimer’s disease.

Share

Related News

Cointime share card
Long-press the image to save or share
Pitch us Community Feedback